<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38175151</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study.</ArticleTitle><Pagination><StartPage>e29333</StartPage><MedlinePgn>e29333</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29333</ELocationID><Abstract><AbstractText>Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID-19, but the effect of treatment during acute infection on risk of Long COVID is unknown. We hypothesized that nirmatrelvir treatment during acute SARS-CoV-2 infection reduces risk of developing Long COVID and rebound after treatment is associated with Long COVID. We conducted an observational cohort study within the Covid Citizen Science (CCS) study, an online cohort study with over 100&#x2009;000 participants. We included vaccinated, nonhospitalized, nonpregnant individuals who reported their first SARS-CoV-2 positive test March-August 2022. Oral nirmatrelvir/ritonavir treatment was ascertained during acute SARS-CoV-2 infection. Patient-reported Long COVID symptoms, symptom rebound and test-positivity rebound were asked on subsequent surveys at least 3 months after SARS-CoV-2 infection. A total of 4684 individuals met the eligibility criteria, of whom 988 (21.1%) were treated and 3696 (78.9%) were untreated; 353/988 (35.7%) treated and 1258/3696 (34.0%) untreated responded to the Long COVID survey (n&#x2009;=&#x2009;1611). Among 1611 participants, median age was 55 years and 66% were female. At 5.4&#x2009;&#xb1;&#x2009;1.3 months after infection, nirmatrelvir treatment was not associated with subsequent Long COVID symptoms (odds ratio [OR]: 1.15; 95% confidence interval [CI]: 0.80-1.64; p&#x2009;=&#x2009;0.45). Among 666 treated who answered rebound questions, rebound symptoms or test positivity were not associated with Long COVID symptoms (OR: 1.34; 95% CI: 0.74-2.41; p&#x2009;=&#x2009;0.33). Within this cohort of vaccinated, nonhospitalized individuals, oral nirmatrelvir treatment during acute SARS-CoV-2 infection and rebound after nirmatrelvir treatment were not associated with Long COVID symptoms more than 90 days after infection.</AbstractText><CopyrightInformation>&#xa9; 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Durstenfeld</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-7612-3352</Identifier><AffiliationInfo><Affiliation>Division of Cardiology at ZSFG, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Disease, &amp; Global Medicine, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peyser</LastName><ForeName>Noah D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isasi</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Population Health, Albert Einstein College of Medicine, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carton</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Louisiana Public Health Institute, New Orleans, Louisiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrich</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of HIV, Infectious Disease, &amp; Global Medicine, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olgin</LastName><ForeName>Jeffrey E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pletcher</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beatty</LastName><ForeName>Alexis L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Epidemiology and Biostatistics, Department of Medicine, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>Gregory M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, UCSF, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsue</LastName><ForeName>Priscilla Y</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Division of Cardiology at ZSFG, Department of Medicine, University of California, San Francisco (UCSF), San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI158013</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>INV-017206</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI157875</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI167648</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HL143961</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AI112393</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>PCORI</Acronym><Agency>Patient-Centered Outcomes Research Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>U2C EB021881</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI147159</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Paxlovid</Keyword><Keyword MajorTopicYN="N">nirmatrelvir</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of COVID-19</Keyword><Keyword MajorTopicYN="N">rebound</Keyword></KeywordList><CoiStatement><b>Disclosures/Conflicts of Interest:</b> Dr. Peluso has served as a consultant for AstraZeneca and Gilead Sciences, outside the submitted work. Dr. Beatty was formerly employed by (2018&#x2013;2019) and held stock in (2019&#x2013;2021) Apple Inc. All other authors report no conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>4</Day><Hour>12</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>4</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38175151</ArticleId><ArticleId IdType="mid">NIHMS1951878</ArticleId><ArticleId IdType="pmc">PMC10786003</ArticleId><ArticleId IdType="doi">10.1002/jmv.29333</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, &amp; Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. The Lancet Infectious Diseases, 2022; 22(4): e102&#x2013;e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A, Iwagami M, Yasuhara J, Takagi H, Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;895 e820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Antar AAR, Yu T, Demko ZO, et al. Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection. Front Immunol. 2023; 14:1147549. doi:10.3389/fimmu.2023.1147549</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1147549</ArticleId><ArticleId IdType="pmc">PMC10176965</ArticleId><ArticleId IdType="pubmed">37187756</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612(7941):758&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y). 2022;3(6):371&#x2013;387 e379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deeks SG, Mustapic M, et al. SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. Ann Neurol. 2022;91(6):772&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082480</ArticleId><ArticleId IdType="pubmed">35285072</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Swank ZN, Goldberg SA, et al. Plasma-based antigen persistence in the post-acute phase of SARS-CoV-2 infection. medRxiv. 2023:2023.2010.2024.23297114.</Citation><ArticleIdList><ArticleId IdType="pubmed">38604216</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Ryder D, Flavell R, et al. Multimodal Molecular Imaging Reveals Tissue-Based T Cell Activation and Viral RNA Persistence for Up to 2 Years Following COVID-19. medRxiv. 2023:2023.2007.2027.23293177.</Citation></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397&#x2013;1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Anglin K, Durstenfeld MS, et al. Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies. Pathog Immun. 2022;7(1):95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9254867</ArticleId><ArticleId IdType="pubmed">35800257</ArticleId></ArticleIdList></Reference><Reference><Citation>Visvabharathy L, Orban ZS, Koralnik IJ. Case report: Treatment of long COVID with a SARS-CoV-2 antiviral and IL-6 blockade in a patient with rheumatoid arthritis and SARS-CoV-2 antigen persistence. Front Med (Lausanne). 2022;9:1003103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9537824</ArticleId><ArticleId IdType="pubmed">36213654</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng LN, Bonilla HF, Shafer RW, Miglis MG, Yang PC. The Use of Nirmatrelvir-ritonavir in a Case of Breakthrough Long COVID. Exploratory Research and Hypothesis in Medicine. 2023;000(000):000&#x2013;000.</Citation></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition. JAMA Intern Med. 2023;183(6):554&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema KL, Berry K, Streja E, et al. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes. Ann Intern Med. 2023;176(6):807&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10243488</ArticleId><ArticleId IdType="pubmed">37276589</ArticleId></ArticleIdList></Reference><Reference><Citation>Congdon S, Narrowe Z, Yone N, et al. Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study. Scientific Reports. 2023;13(1):19688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10640584</ArticleId><ArticleId IdType="pubmed">37951998</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty AL, Peyser ND, Butcher XE, et al. The COVID-19 Citizen Science Study: Protocol for a Longitudinal Digital Health Cohort Study. JMIR Res Protoc. 2021;10(8):e28169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8407439</ArticleId><ArticleId IdType="pubmed">34310336</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, Peluso MJ, Peyser ND, et al. Factors Associated With Long COVID Symptoms in an Online Cohort Study. Open Forum Infect Dis. 2023;10(2):ofad047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9945931</ArticleId><ArticleId IdType="pubmed">36846611</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. American Journal of Epidemiology. 2016;183(8):758&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">17938396</ArticleId></ArticleIdList></Reference><Reference><Citation>Administration FaD. Fact Sheet for Healthcare Providers. In:2022.</Citation></Reference><Reference><Citation>Pfizer Reports Additional Data on PAXLOVID&#x2122; Supporting Upcoming New Drug Application Submission to U.S FDA; [press release]. 2022.</Citation></Reference><Reference><Citation>Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients. Clin Infect Dis. 2022;76(3):e342&#x2013;e349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214014</ArticleId><ArticleId IdType="pubmed">35653428</ArticleId></ArticleIdList></Reference><Reference><Citation>Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study. Ann Intern Med. 2023;176(1):77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9753458</ArticleId><ArticleId IdType="pubmed">36508742</ArticleId></ArticleIdList></Reference><Reference><Citation>Wai AK, Chan CY, Cheung AW, et al. Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. Lancet Reg Health West Pac. 2023;30:100602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9532222</ArticleId><ArticleId IdType="pubmed">36212676</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah MM, Joyce B, Plumb ID, et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19 - United States, April-September 2022. Am J Transplant. 2023;23(1):150&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9833372</ArticleId><ArticleId IdType="pubmed">36695616</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CKH, Au ICH, Lau KTK, Lau EHY, Cowling BJ, Leung GM. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong&#x2019;s omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022;22(12):1681&#x2013;1693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9401976</ArticleId><ArticleId IdType="pubmed">36029795</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen K, Makkar SR, Sahner D, et al. Paxlovid (nirmatrelvir/ritonavir) effectiveness against hospitalization and death in N3C: A target trial emulation study. medRxiv. 2023:2023.2005.2026.23290602.</Citation></Reference><Reference><Citation>Qi T, Jin Y, Wang H, et al. Nirmatrelvir-ritonavir Therapy and COVID-19 Vaccination Improve Clinical Outcomes of SARS-CoV-2 Omicron Variant Infection. J Med Virol. 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10107277</ArticleId><ArticleId IdType="pubmed">36651302</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhao D, Liu X, Chen X, Xiao W, Feng L. Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants. J Med Virol. 2023;95(1):e28443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9880690</ArticleId><ArticleId IdType="pubmed">36579782</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R, Dani S, Khadke S, et al. Incidence of Symptoms Associated with Post-Acute Sequelae of SARS-CoV-2 infection in Non-Hospitalized Vaccinated Patients Receiving Nirmatrelvir-Ritonavir. medRxiv. 2023:2023.2004.2005.23288196.</Citation></Reference><Reference><Citation>Wong GL, Yip TC, Lai MS, Wong VW, Hui DS, Lui GC. Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir. JAMA Netw Open. 2022;5(12):e2245086.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9856258</ArticleId><ArticleId IdType="pubmed">36472873</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganath N, O&#x2019;Horo JC, Challener DW, et al. Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons. Clinical Infectious Diseases. 2022;76(3):e537&#x2013;e539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384250</ArticleId><ArticleId IdType="pubmed">35698452</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelstein GE, Boucau J, Uddin R, et al. SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study. Ann Intern Med. 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10644265</ArticleId><ArticleId IdType="pubmed">37956428</ArticleId></ArticleIdList></Reference><Reference><Citation>Uhm JS, Ahn JY, Hyun J, et al. Patterns of viral clearance in the natural course of asymptomatic COVID-19: Comparison with symptomatic non-severe COVID-19. Int J Infect Dis. 2020;99:279&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7403105</ArticleId><ArticleId IdType="pubmed">32763446</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, Peluso MJ, Kaveti P, et al. Reduced Exercise Capacity, Chronotropic incompetence, and early systemic inflammation in cardiopulmonary phenotype long coronavirus disease 2019. J Infect Dis. 2023; 228(5): 542&#x2013;554. doi:10.1093/infdis/jiad131</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad131</ArticleId><ArticleId IdType="pmc">PMC10686699</ArticleId><ArticleId IdType="pubmed">37166076</ArticleId></ArticleIdList></Reference><Reference><Citation>Apple AC, Oddi A, Peluso MJ, et al. Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. Ann Clin Transl Neurol. 2022;9(2):221&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862406</ArticleId><ArticleId IdType="pubmed">35043593</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>